Results 221 to 230 of about 146,670 (267)
Some of the next articles are maybe not open access.

Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer

Thyroid, 2020
Background: Management of patients with advanced medullary thyroid cancer (MTC) remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) vandetanib and cabozantinib have been approved for the treatment of progressive MTC based on ...
V. Koehler   +9 more
semanticscholar   +1 more source

Medullary Thyroid Cancer

2021
In this chapter while following the clinical course of a patient diagnosed with medullary thyroid cancer (MTC), the reader will be acquainted with the basic clinical features, diagnosis, and treatment of this rare tumor.
Victor A. Gall, Amanda M. Laird
openaire   +2 more sources

Medullary Thyroid Cancer

Endocrine Abstracts, 2015
Medullary thyroid cancer (MTC) is an uncommon disease, accounting for 3–10 % of all thyroid cancers worldwide [1–3]. The German literature contains reports of a thyroid malignancy with amyloid deposits as early as 1906, but it was not until 1959 when Hazard and co-workers reported on a clinicopathological, solid arrangement of cells, which represented ...
Laura Chin-Lenn, Janice L. Pasieka
  +4 more sources

Sporadic Medullary Thyroid Cancer

2009
Medullary thyroid cancer (MTC), is a tumor of the parafollicular / c-cells of the thyroid gland. These cells are derived from the embryonic neural crests and make up 1% of the thyroid cells. C-cells can be found anywhere in the gland but are concentrated in the upper poles of the thyroid lobes.
Adrian, Harvey, Janice L, Pasieka
openaire   +2 more sources

Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial

Thyroid, 2020
Background: Thyroid cancer is the most common endocrine tumor with an increasing incidence. Limited treatment options are available for patients with advanced or recurrent metastatic disease, resulting in a poor prognosis.
Jia-ying Chen   +14 more
semanticscholar   +1 more source

The neurotransmitter calcitonin gene-related peptide shapes an immunosuppressive microenvironment in medullary thyroid cancer

Nature Communications
Neurotransmitters are key modulators in neuro-immune circuits and have been linked to tumor progression. Medullary thyroid cancer (MTC), an aggressive neuroendocrine tumor, expresses neurotransmitter calcitonin gene-related peptide (CGRP), is insensitive
Yingtong Hou   +18 more
semanticscholar   +1 more source

Medullary Thyroid Cancer

Surgical Clinics of North America, 1995
Medullary thyroid cancer is a tumor of the thyroid C cells that occurs in sporadic and hereditary clinical settings. Genetic testing of at-risk individuals is available and has been applied to patient management. Plasma calcitonin levels are a very sensitive marker for the presence of disease.
openaire   +2 more sources

Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction.

British Journal of Surgery, 2020
BACKGROUND Medullary thyroid cancer can be subdivided during surgery into tumours with or without a desmoplastic stromal reaction (DSR). DSR positivity is regarded as a sign of disposition to metastasize.
M. Niederle   +6 more
semanticscholar   +1 more source

Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies

International Journal of Molecular Sciences
Thyroid cancer (TC) invariably remains the most prevalent endocrine cancer in the world. Major histological forms of TC include papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic thyroid carcinoma (ATC), each of which has a unique ...
Alicja Forma   +6 more
semanticscholar   +1 more source

Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer

Thyroid, 2018
Background: The prognosis of advanced or metastatic medullary thyroid carcinoma (MTC) is poor, and there are few therapeutic options. Anlotinib has previously shown promising antitumor activity on MTC in preclinical models and a Phase I study. This Phase
Yongkun Sun   +11 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy